A splashy large study and two small studies suggest IV Mg in pre-hydration fluids can decrease the risk of cisplatin kidney injury.
Gupta et al. JAMA Oncol (2025): doi:10.1001/jamaoncol.2025.0756
PRAGMATIC. ESMO Open (2022): https://doi.org/10.1016/j.esmoop.2021.100351
Yamamoto et al. Anticancer Res (2015): https://pubmed.ncbi.nlm.nih.gov/25862878/
--------
15:48
TI-CH, Updates on dostarlimab, ventoclax, & zongertinib
This episode summarizes recent updates on:
Tumor infiltrating clonal hematopoiesis (TI-CH) and its apparent negative impact on solid tumors (https://www.nejm.org/doi/full/10.1056/NEJMoa2413361)
Updated dostarlimab data on MMRd use in rectal cancer and other solid tumors in the neoadjuvant (definitive?!?!) setting (https://www.nejm.org/doi/full/10.1056/NEJMoa2404512)
Phase 1 study of 7 + 3 + Venetoclax (https://doi.org/10.1182/blood.2024026700)
Zongertinib, a new HER2 TKI (https://www.nejm.org/doi/full/10.1056/NEJMoa2503704)
--------
12:11
BRCA Reversion Mutations
BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors.
Bibliography:
1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715
2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933
3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015
--------
12:43
HOPA 25 Recap
Recapping HOPA 25 and Portland
*Great food (not discussed, the most excellent ETSU dinner at Arden)
*COCOON
*Pharmacists make everyone's job easier and keep patients out of the ED
*A few more tidbits too!
--------
11:45
Expanded Approvals for Durvalumab, Lu 177 vt; Portland Preview
FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
New Zealand